New Commercial Research Delivery Centre in Lothian set to expand UK capacity to deliver commercial clinical trials

A dedicated Commercial Research Delivery Centre (CRDC) opened its doors at the Western General Hospital (WGH) thanks to a new UK- wide investment programme. 

The development of CRDCs in Scotland has been made possible through funding from the 2024 Voluntary scheme for branded medicines Pricing, Access and Growth (VPAG).The agreement between the UK Government and the Association of the British Pharmaceutical Industry (ABPI), involves an investment programme across the four UK nations, which includes the establishment of 21 CRDCs. 

In Scotland, CRDCs are supported by the CSO and coordinated through NRS. Each CRDC works closely with NHS Boards, local research teams, and national research infrastructure to ensure that clinical trials are accessible, inclusive, and well-supported. 

They are designed to make it easier for commercial sponsors to conduct trials in Scotland, and deliver them more efficiently, by supporting all phases of the research delivery pathway – from early feasibility through to recruitment and implementation. 

Together, the partnership of Scottish CRDCs aims to provide a globally competitive, once-for-Scotland delivery network for commercial trials for the benefit of Scottish patients, the NHS and the Scottish economy. 

Located in Ward 22 at the Western General Hospital, the new CRDC will support the expansion and enhancement of the UK’s capacity to deliver pharmaceutical commercial clinical trials. 

The ward will also become the new home of the Clinical Infection Research Group (CIRG), which is running its first global trial evaluating the use of a new drug for the treatment of chronic pulmonary aspergillosis (CPA).

Gerard Smith (age 61), the first patient to be recruited and dosed at the new facility, shared his story, highlighting why it was important for him to participate in the study. “I used to work as a self-employed painter and decorator with no health issues until I was diagnosed with COPD and lung cancer in December 2022. Soon after, I underwent a right upper lobectomy before being diagnosed with chronic pulmonary aspergillosis and a right apical aspergilloma. Unfortunately, I developed a resistance to the drug used for treatment. If the new trial is successful, it will enable me to be able to manage my condition long term.

“I decided to take part in the study because I believe that, unless eligible people are prepared to do so, no progress regarding alternative medication would be possible. I hope that this will benefit not only me, but also others in the future, improving our quality of life and extending our life expectancy”.

Professor Neeraj Dhaun (CRF Director) said: “The opening of the new Commercial Research Delivery Centre at the Western General Hospital marks an exciting step forward for research in Lothian and across Scotland. Supported through a public–private partnership between the government and the pharmaceutical industry, the Centre will accelerate and strengthen the delivery of commercial clinical research. 

“This investment will give patients faster access to innovative studies, support collaboration with industry, and help boost the UK’s global competitiveness in life sciences. We are delighted to see this important facility come to fruition.”

Tracey Gillies, Medical Director at NHS Lothian said: “NHS Lothian has a long history of providing exceptional, globally leading healthcare and we’re thrilled that the Western General Hospital will be home to the new CRDC. We look forward to seeing the impact that this increased investment and access to clinical commercial research will have for patients in Lothian and across Scotland.”